Dr. Bo Liu 刘波
Chief Physician
Medical Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Individualized targeted therapy and multidisciplinary treatment for solid tumors, including lung, breast, gastrointestinal, lymphoma, bone, and reproductive system cancers. Management of oncologic emergencies such as malignant effusions.
Dr. Liu is Chief Physician and Director of the Seventh Internal Medicine Department. Holding a master’s degree in oncology, Dr. Liu has extensive clinical experience in dose-dense therapy, chronotherapy, and continuous intravenous chemotherapy. Dr. Liu has published SCI articles, edited multiple monographs, and participated in numerous domestic and international clinical trials.
Professional roles
- Chair, Palliative Medicine Branch, Shandong Medical Association
- Standing Committee Member, Cancer Rehabilitation and Palliative Care Professional Committee, China Anti-Cancer Association
- Member, Nutrition and Supportive Care Professional Committee, China Anti-Cancer Association
- Vice Chair, Brain Tumor Professional Committee, Shandong Anti-Cancer Association
Name order: in Chinese the family name comes first (Liu Bo). Papers usually list the name as Bo Liu or Liu B.
Selected publications
92 papers on PubMed matched by name and affiliation; 28 as first or senior author since 2016. Most recent first- or senior-author papers:
- Pharm Sci Adv, 2026 (senior author): Corrigendum to "Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib" [Pharmaceut. Sci. Adv. 4, (2026), 100125]. PubMed 42866109
- Pharm Sci Adv, 2026 (senior author): Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib. PubMed 42256552
- Bioorg Med Chem Lett, 2026 (senior author): Design, synthesis, and biological evaluation of sphingosine kinase 2 inhibitors derived from K145. PubMed 42049117
- Front Oncol, 2026 (senior author): Case Report: Sustained complete response achieved in a patient with advanced HER-2 positive gastric cancer after 4 years of chemotherapy-free treatment. PubMed 42057818
- J Nanobiotechnology, 2026 (first author): Targeting redox metabolism and low-dose radiotherapy synergistically activate cGAS-STING pathway to improve NK cell therapy efficacy in hepatocellular carcinoma. PubMed 41731500
- Bioorg Med Chem, 2026 (senior author): Novel oxadiazole analogs as anticancer agents: Design, synthesis, in vitro and in vivo biological evaluation, and computer studies of sphingosine kinase inhibitors. PubMed 41273810
- Free Radic Biol Med, 2026 (first author): Hepatic soluble epoxide hydrolase mediates osteoclastogenesis by suppressing the Nrf2 signaling pathway: a novel mechanism of redox imbalance in osteoporosis. PubMed 41265499
- Front Physiol, 2025 (first author): The critical role of inflammation in osteoporosis prediction unveiled by a machine learning framework integrating multi-source data. PubMed 41451124
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion